SLU-PP-332

No study in the cited record has given SLU-PP-332 to a person. What is known comes from mice, cultured cells and test-tube chemistry. It draws attention because, in the 2023 mouse work that introduced it, sedentary mice treated for a week ran about 70 percent longer and about 45 percent further on a treadmill than untreated mice, and because its own developers describe it as an exercise mimetic.

It is also not a peptide. SLU-PP-332 is a small synthetic molecule that switches on the estrogen-related receptors, a family of nuclear receptors that sit over mitochondrial and fuel-handling genes in muscle, heart and liver. It is listed alongside peptides because it turns up in the same performance conversations, not because it shares their chemistry or biology.

SLU-PP-332 is a synthetic agonist of all three estrogen-related receptors: ERR-alpha, ERR-beta and ERR-gamma. Its developers made it by modifying GSK4716, an older compound that activated only ERR-beta and ERR-gamma, and the change bought roughly 50-fold more ERR-alpha potency. In cell reporter assays it activated ERR-alpha at 98 nM, ERR-beta at 230 nM and ERR-gamma at 430 nM, so it leans toward ERR-alpha but is not selective enough to hit one receptor alone.

The name misleads. The estrogen-related receptors resemble estrogen receptors in structure but do not bind the body's estrogen ligands, and SLU-PP-332 did not change the activity of estrogen receptor alpha or beta when tested. A 2026 chemistry paper calls it a widely used chemical probe: a research tool built to switch a receptor on in animals so its effects can be studied.

A Receptor That Is Already On

Most nuclear receptors sit idle until a hormone binds them. The ERRs are different: all three drive transcription without any ligand, and they are concentrated in high-energy tissues such as skeletal muscle, heart, brain, fat and liver. Loss of ERR-alpha or ERR-gamma in mice reduces muscle oxidative capacity and endurance. SLU-PP-332 pushes an already active receptor harder, which is why it was notable that a small molecule could do it at all.

What It Switched On in Mouse Muscle

In mouse muscle cells in culture it raised maximal mitochondrial respiration and mitochondrial content. In mice it produced a more oxidative muscle profile, more mitochondria, more mitochondrial DNA and more type IIa oxidative fibers. A single injection in sedentary mice raised Ddit4, a gene that drives the acute aerobic exercise program, about threefold within an hour, against about sixfold from a 40-minute run. Another exercise gene, Slc25a25, rose about elevenfold under either the run or the compound. Both effects faded within three hours, the same short window seen after exercise.

Why ERR-Alpha Matters Here

The endurance gain depended on ERR-alpha in muscle. Mice lacking ERR-alpha only in skeletal muscle (five per group) ran no further on SLU-PP-332 than on vehicle, while their normal littermates improved. In muscle cells from those knockout mice, Ddit4 induction disappeared without ERR-alpha but survived without ERR-gamma. The authors add a caveat about their own data: at the doses used, all three ERRs are activated, so the compound cannot cleanly separate what each receptor does.

Running longer is a mouse result. The 70 percent endurance gain came from sedentary laboratory mice treated by injection and run to exhaustion on a treadmill. Nobody has measured endurance, strength, body composition or anything else in a person taking SLU-PP-332, so the mouse number cannot be carried over as an expected effect.

Exercise mimetic describes genes, not training. The compound switched on some of the same acute exercise genes as a run, briefly. It did not reproduce the mechanical loading, cardiovascular demand or repeated stimulus that make up training, and in the obese-mouse work it left lean mass unchanged.

The fat-loss data is from obese mice on a high-fat diet. In lean mice, body weight did not move after four weeks. The weight difference appeared only in mice already made obese by diet, which is a narrower finding than it gets credit for.

A chemical probe is not a drug candidate. Its developers published a full program of analogues in 2026 precisely because SLU-PP-332 has poor solubility and room for better stability. Its own makers treat it as a starting point.

Safety in people is unknown. There are no human exposure data in the cited record, so there is no adverse event profile, no tolerability data and no interaction data to report.

The animal signals are short and limited. Mice treated for ten days showed no overt toxicity and normal blood counts, electrolytes and creatine kinase. In ob/ob mice the study was cut to 12 days because the animals tolerated twice-daily injections poorly. Liver enzymes did not rise in obese mice over 28 days.

The 2026 metabolite study exists so that anti-doping laboratories can detect use of the compound. It mapped 22 metabolites formed by human liver enzymes in vitro, and its authors note that further work is needed to fully establish their structures.

SLU-PP-332 is a good example of a well-designed mouse experiment being read as a product description. The research itself is careful: it shows that pushing ERR-alpha in mouse muscle triggers a short burst of exercise genes, more mitochondria, more oxidative fibers and longer treadmill runs, and that the endurance effect vanishes when ERR-alpha is removed from muscle.

What that tells a reader is that ERR-alpha is a real lever on muscle energy metabolism in mice, and that a small molecule can pull it. What it does not tell anyone is the effect, dose response, duration or risk in a human body, because those questions have not been asked in a person. The most recent paper in the record is about making a better molecule, which says something about how far this one is from the clinic.

Not a peptide. SLU-PP-332 is a small synthetic molecule, an acyl hydrazone built on an older ERR agonist scaffold. It acts on nuclear receptors inside the cell, not through the receptor signaling most peptides here use.

Not tested in people. Every endurance, metabolic and muscle finding comes from mice or cell culture. The only human material in the record is liver tissue in a test tube.

Not approved, and not on the FDA compounding lists. It is not an approved drug and does not appear on the FDA Category 1 or Category 2 lists; no FDA nomination record was found. FDA has said it does not intend to categorise substances nominated on or after 7 January 2025, so absence from those lists says nothing about safety or legality.

Not permitted in tested sport. It is not named on the WADA Prohibited List, but it falls under S0, Non-Approved Substances, which bans at all times any pharmacological substance without current approval by a governmental health authority for human therapeutic use. The metabolic modulator class does not carry a general catch-all, so S0 is the route that applies.

I find SLU-PP-332 genuinely interesting, and I want to be precise about why. The knockout experiment is the elegant part: take ERR-alpha out of muscle and the endurance effect disappears. That is a clean piece of mechanism, and it tells you something real about how muscle decides to become more oxidative.

What I will not do is turn a treadmill result in sedentary mice into a promise about your conditioning. There is no human dose, no human safety record and no human outcome anywhere in what I have read, and the people who made the compound are already working on replacing it. If you compete in tested sport, it is banned at all times under S0. If you want what the mice got, the reliable way to switch on that gene program is still the run itself.